Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Glycorex Transplantation

1.85 SEK

-2.63 %

Less than 1K followers

GTAB B

NGM Main Regulated

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.63 %
-1.60 %
-8.42 %
-19.21 %
-9.31 %
+3.06 %
-55.74 %
-85.02 %
-81.78 %

Glycorex Transplantation is active in biotechnology. The company conducts research, development and marketing in the field of organ transplantation. The company's main product enables transplants regardless of the blood type of the donor or recipient. Transplantation using the company's product is carried out on a global level. Glycorex Transplantation was founded in 1996 and has its headquarters in Lund.

Read more
Market cap
145.88M SEK
Turnover
59.17K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Press release8/13/2025, 10:50 AM

Glycorex Transplantation (GTAB B): First ABO-incompatible organ transplantion in Morocco with Glycosorb® ABO

Glycorex Transplantation
Press release2/28/2025, 8:06 AM

Glycorex Transplantation (GTAB B): Enters distribution agreement in Greece for Glycosorb® ABO in the field of transfusion and transplantation

Glycorex Transplantation
Press release2/18/2025, 2:26 PM

Glycorex Transplantation AB: First ABO-incompatible transplantation in Portugal with Glycosorb® ABO

Glycorex Transplantation

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release12/23/2024, 7:30 AM

Glycorex Transplantation AB (GTAB B): First blood group-incompatible pediatric heart transplantation in Austria using Glycosorb® ABO

Glycorex Transplantation
Press release9/13/2024, 9:15 AM

Glycorex Transplantation AB (GTAB B): Results from Norwegian platelet evaluation presented at conference

Glycorex Transplantation
Press release8/13/2024, 8:00 AM

Glycorex Transplantation AB: First ABO-incompatible transplantation in Argentina with Glycosorb® ABO

Glycorex Transplantation
Press release5/13/2024, 6:20 AM

Glycorex Transplantation: Glycosorb® ABO is pushing the boundaries in paediatric blood group incompatible heart transplantation

Glycorex Transplantation
Press release5/8/2024, 11:24 AM

Glycorex Transplantation: First publication from South Africa and first stem cell transplantation performed in Mexico

Glycorex Transplantation
Press release2/20/2024, 11:39 AM

Glycorex Transplantation (GTAB B): Signs agreement with distributor in Romania

Glycorex Transplantation
Regulatory press release11/29/2023, 9:31 AM

Glycorex Transplantation AB: Entering into an agreement with Bio-Rad Laboratories, Inc.

Glycorex Transplantation
Regulatory press release11/29/2023, 7:00 AM

Glycorex Transplantation AB (publ): Interim Report January - September 2023

Glycorex Transplantation
Regulatory press release8/30/2023, 6:00 AM

Glycorex Transplantation AB (publ): Interim Report January - June 2023

Glycorex Transplantation
Regulatory press release5/24/2023, 6:00 AM

Glycorex Transplantation AB (publ): Interim Report January - March 2023

Glycorex Transplantation
Regulatory press release4/28/2023, 4:00 PM

Annual Report 2022 Glycorex Transplantation AB (publ)

Glycorex Transplantation
Press release3/9/2023, 2:00 PM

Glycorex Transplantation: Published study from the US shows promising results on the use of Glycosorb® ABO to provide low-titer group O whole blood

Glycorex Transplantation
Regulatory press release2/28/2023, 7:00 AM

Glycorex Transplantation: Year-end Report 2022

Glycorex Transplantation
Press release2/20/2023, 11:00 AM

Glycorex Transplantation: The first blood group incompatible kidney transplant using Glycosorb® ABO performed in South Africa

Glycorex Transplantation
Press release1/31/2023, 3:00 PM

Glycorex Transplantation: Glycorex strengthens the organization to place additional force behind the growth strategy Going 4 Growth

Glycorex Transplantation
Regulatory press release11/24/2022, 7:00 AM

Glycorex Transplantation AB (GTAB B): Interim report January - September 2022

Glycorex Transplantation
Press release9/27/2022, 1:23 PM

Glycorex Transplantation (GTAB B): Glycosorb[®] ABO used at the largest heart transplant center in Germany

Glycorex Transplantation
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.